公开(公告)号：US20190389836A1

公开(公告)日：2019-12-26

申请号：US16481772

申请日：2018-01-29

Applicant: BIOGEN MA INC.

Inventor： Andrew George Capacci ,  Michael Dechantsreiter ,  Istvan Enyedy ,  John H. Jones ,  Edward Yin-Shiang Lin ,  Brian Stuart Lucas ,  Bin Ma

IPC: C07D401/06 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D215/14 ,  C07D405/14 ,  C07D471/04 ,  C07D451/02

Abstract: Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.

公开(公告)号：US20240279197A1

公开(公告)日：2024-08-22

申请号：US18545312

申请日：2023-12-19

Applicant: BIOGEN MA INC.

Inventor： Andrew George Capacci ,  Edward Yin Shiang Lin ,  Brian Stuart Lucas

IPC: C07D311/74

CPC classification number: C07D311/74

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.

公开(公告)号：US11465963B2

公开(公告)日：2022-10-11

申请号：US16765614

申请日：2018-11-20

Applicant: BIOGEN MA INC.

Inventor： Andrew George Capacci ,  Edward Yin Shiang Lin ,  Brian Stuart Lucas

IPC: C07C255/47 ,  C07D317/72

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.

公开(公告)号：US20230121818A1

公开(公告)日：2023-04-20

申请号：US17788127

申请日：2020-12-23

Applicant: BIOGEN MA INC.

Inventor： Bin Ma ,  Brian T. Hopkins ,  Isaac Marx ,  Jürgen Schulz ,  George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Andrew George Capacci

IPC: C07D401/14 ,  C07D413/12 ,  C07D471/04 ,  C07D403/12 ,  C07D403/10 ,  C07D495/04 ,  C07D401/12 ,  C07D413/14

Abstract: Provided are compounds of Formula (I′) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R8, R9, R11A, R11B, R12, Ri, Rii, A1, A2, Q1, Q2, Q3, X, W, and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

公开(公告)号：US20210387960A1

公开(公告)日：2021-12-16

申请号：US17333498

申请日：2021-05-28

Applicant: BIOGEN MA INC.

Inventor： Andrew George Capacci ,  Edward Yin Shiang Lin ,  Brian Stuart Lucas

IPC: C07D311/74

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.

公开(公告)号：US20200299230A1

公开(公告)日：2020-09-24

申请号：US16765614

申请日：2018-11-21

Applicant: BIOGEN MA INC.

Inventor： Andrew George Capacci ,  Edward Yin Shiang Lin ,  Brian Stuart Lucas

IPC: C07C255/47 ,  C07D317/72

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.

公开(公告)号：US20240083900A1

公开(公告)日：2024-03-14

申请号：US18036853

申请日：2021-11-12

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Isaac Marx ,  Jürgen Schulz ,  George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Edward Yin-Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Thomas Purgett ,  Andrew George Capacci ,  Simone Sciabola

IPC: C07D487/04 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: Provided are compounds of Formula (I′): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.

公开(公告)号：US20210340107A1

公开(公告)日：2021-11-04

申请号：US17221358

申请日：2021-04-02

Applicant: BIOGEN MA INC.

Inventor： Brian Stuart Lucas ,  Edward Yin Shiang Lin ,  Andrew George Capacci ,  Zhili Xin ,  Istvan Enyedy ,  TeYu Chen ,  John H. Jones ,  Kurt D. van Vloten

IPC: C07D217/04 ,  C07D217/08 ,  C07D217/20 ,  C07D217/22 ,  C07D223/14 ,  C07D311/74 ,  C07D401/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06 ,  C07D413/06 ,  C07D498/04

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US10968181B2

公开(公告)日：2021-04-06

申请号：US16473667

申请日：2017-12-27

Applicant: BIOGEN MA INC.

Inventor： Brian Stuart Lucas ,  Edward Yin-Shiang Lin ,  Andrew George Capacci ,  Zhili Xin ,  Istvan Enyedy ,  TeYu Chen ,  John H. Jones ,  Kurt D. van Vloten

IPC: C07D311/76 ,  C07D217/04 ,  C07D217/08 ,  C07D223/16 ,  C07D498/14 ,  A61K31/352 ,  A61K31/47 ,  C07D217/20 ,  C07D217/22 ,  C07D223/14 ,  C07D311/74 ,  C07D401/04 ,  C07D401/06 ,  C07D405/04 ,  C07D405/06 ,  C07D413/06 ,  C07D498/04

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20190389830A1

公开(公告)日：2019-12-26

申请号：US16481743

申请日：2018-01-26

Applicant: BIOGEN MA INC.

Inventor： Andrew George Capacci ,  Edward Yin-Shiang Lin ,  Brian Stuart Lucas

IPC: C07D311/74

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.